Company Name Change - Brand Institute, inc.



			Company Name Change Brand Institute is the premier full-service branding agency dedicated to strategic and innovative brand naming and identity solutions. We strive to exceed the expectations of every client by combining leading-edge market research with the highest levels of client service, integrity and brand management FDA expands indication for Ortho-McNeil's Topamax The Food and Drug Administration approved Ortho-McNeil Neurologics Inc.'s Topamax (topiramate) tablets and sprinkle capsules as initial monotherapy for patients aged 10 years or older with partial-onset or primary generalized tonic-clonic seizures. Topamax was also indicated as add-on therapy for patients aged 2 years or older with primary generalized tonic-clonic seizures, partial-onset seizures or seizures associated with Lennox-Gastaut syndrome. Effectiveness for the new indication was demonstrated in a double-blind trial of 470 patients with partial-onset or primary generalized tonic-clonic seizures; all patients included in the trial had no more than two seizures during the three-month period prior to enrollment. Participants were randomized to receive 50 mg/day or 400 mg/d of Topamax. The trial's primary efficacy assessment was a comparison between the groups in the time to first seizure. Based on Kaplan-Meier survival curves, the 400 mg/d dose was favored over the lower dose. The recommended monotherapy dose of Topamax in patients aged 10 years or older is 400 mg/d, divided into two doses, Ortho-McNeil said, noting that approximately 58 percent of patients who were randomized to the higher dosage actually achieved this level during the trial. The mean dose achieved was 275 mg/d. The safety and effectiveness of Topamax as monotherapy have not yet been established in controlled trials of patients who switch from a regimen of other anticonvulsants, according to Ortho-McNeil. "Antiepilepsy medications . . . are selected based on seizure type; however, the specific seizure type may not always be obvious at the time of diagnosis," said Dr. Tracy Glauser, director of the Comprehensive Epilepsy Center at the Cincinnati Children's Hospital. "A treatment like Topamax, which provides coverage for both partial-onset and primarily generalized tonic-clonic seizures, offers doctors an option in situations where differentiating between these seizure types is difficult." Company Name Change Schering-Plough's Avelox approved for fifth indication Schering-Plough Corp. said Avelox (moxifloxacin hydrochloride), a once-daily antibiotic, was approved by the Food and Drug Administration to treat adults with complicated skin and skin structure infections (cSSSIs) caused by methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae or Enterobacter cloacae. This approval marks the fifth indication for Avelox, which has also been approved for the treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia and uncomplicated skin and skin structure infections. Two cSSSI trials were conducted comparing Avelox with a beta-lactam/beta-lactamase inhibitor as a control. Pooled clinical success rates for Avelox versus the comparator were, respectively, 81.6 percent versus 84.8 percent for E. coli, 91.7 percent versus 70 percent for K. pneumoniae and 81.8 percent versus 57.1 percent for E. cloacae. Schering-Plough acquired exclusive U.S. rights to Avelox from Bayer Pharmaceuticals Corp. in October of 2004. Schering-Plough explained that since Bayer developed the drug and holds the associated New Drug Application and patents, Bayer completed the research and FDA submission for this new indication. Company Name Change J&JPRD's Zarnestra deemed not approvable The Food and Drug Administration sent a not approvable letter to Johnson & Johnson Pharmaceutical Research & Development LLC for Zarnestra (tipifarnib), an oral drug intended to treat acute myeloid leukemia in patients aged 65 years or older who are not candidates for standard chemotherapy. The letter said the drug cannot be approved based on the data submitted. Zarnestra's New Drug Application was supported by the results of a single Phase II trial. J&JPRD completed submission of the NDA last December under the Continuous Marketing Application Pilot-1 Program. In May, an FDA advisory committee voted against recommending accelerated approval of the drug, which had previously been granted fast track and orphan drug status. J&JPRD said the company is still committed to developing the drug. "Recognizing the unmet medical need in this area, the company is reviewing the FDA's letter and will determine appropriate next steps," the firm stated. Company Name Change Penwest's beta blocker deemed not approvable by FDA Penwest Pharmaceuticals Co. received a non-approvable letter for its New Drug Application for PW2101, a beta blocker intended to treat hypertension and angina. Reasons cited by the Food and Drug Administration in the non-approvable letter included the drug's kinetic variability among individuals and that "beta blockade as a surrogate for efficacy was not demonstrated across the entire interdosing interval on an individual subject basis," according to Penwest. The company has decided to forgo further attempts to gain approval for the drug because of the time and resources such efforts would require. "We are very disappointed by the FDA's decision," said Robert Hennessey, chief executive officer of Penwest. "We have concluded that given these circumstances, it is not in the best interests of our company and our shareholders to continue with the additional activities we believe would be required for this product." Company Name Change Takeda submits NDA for combination type 2 diabetes drug Takeda Pharmaceuticals North America Inc. submitted a New Drug Application for an oral drug that combines Takeda's Actos (pioglitazone hydrochloride) with sanofi-aventis Group's Amaryl (glimepiride) to treat type 2 diabetes. Actos, which Takeda co-promotes with Eli Lilly and Co., directly targets insulin resistance, while Amaryl, a sulfonylurea, increases the amount of insulin the pancreas produces. The combination of these drugs helps patients with type 2 diabetes manage their blood glucose levels, Takeda said. Amaryl is indicated for patients with type 2 diabetes as adjunctive therapy when diet and exercise alone do not suffice. It can be taken in combination with insulin or metformin, both of which are frequently prescribed diabetes drugs. Actos is a once-daily adjunct to diet and exercise and is approved as monotherapy for type 2 diabetes. It can be prescribed in combination with insulin, sulfonylureas or metformin. Company Name Change Tysabri meets primary, secondary endpoints in Crohn's disease trial Elan Corp. Plc and Biogen Idec Inc.'s Tysabri (natalizumab) met the primary endpoint of clinical response in patients with moderately to severely active Crohn's disease in Phase III testing. Clinical response, defined as a 70-point decrease in Crohn's Disease Activity Index (CDAI) score from baseline, was evaluated at weeks eight and 12. Additionally, the trial, which included 510 patients, achieved all secondary endpoints, including clinical remission (defined as a CDAI score of less than or equal to 150) at weeks eight and 12. Moreover, researchers found no notable differences between Tysabri and placebo in the overall rates of adverse events. The companies voluntarily suspended U.S. sales and all trials of the drug in February based on reports of progressive multifocal leukoencephalopathy (PML), a rare and potentially fatal demyelinating disease of the central nervous system. Participants in this trial had already completed dosing before the suspension took place. The companies said a comprehensive safety evaluation for any possible link to PML is ongoing. "Patient safety remains our top priority," said Dr. Lars Ekman, Elan's president of research and development. He said the companies plan to share data from this and other studies of Tysabri in Crohn's disease with the Food and Drug Administration to determine the future of the drug. Company Name Change Hyphanox shown inferior to Pfizer's Diflucan in Phase III trial Barrier Therapeutics Inc. revealed that the company's oral antifungal candidate, Hyphanox (itraconazole), failed to reach its primary endpoint of therapeutic cure in Phase III testing. The trial, which included 800 participants, was designed to show that a single dose of Hyphanox was not inferior to a single dose of Pfizer Inc.'s Diflucan (fluconazole) in the treatment of vaginal candidiasis, commonly known as vaginal yeast infection. The results of the trial showed that 26 percent of patients treated with Hyphanox reached the primary endpoint compared with 37 percent of patients treated with Diflucan. "The outcome of the study is disappointing," said Dr. Geert Cauwenbergh, Barrier's chief executive officer. "We will continue to analyze the massive amount of data to determine next steps for this indication. The results from this single-dose study for vaginal candidiasis do not affect our confidence in the potential of Hyphanox for the chronic treatment of onychomycosis [nail fungus], for which the active ingredient, itraconazole, is currently approved in the United States." Hyphanox contains a patented formulation of itraconazole, the same active ingredient in Janssen Pharmaceutica Products LP's Sporanox, which is already approved to treat nail fungus. Barrier's stock closed at $7.93, down 46.4 percent, or $6.85, in heavy trading on the Nasdaq. Company Name Change Company Name Change Novartis AG Novartis AG signed an exclusive global license agreement with Arrow Therapeutics Ltd. for A-60444, an investigational treatment for infections resulting from the respiratory syncytial virus (RSV), the most common respiratory virus in infants. The agreement grants Novartis rights to develop, manufacture and commercialize the compound, rights for back-up compounds and a right of first negotiation on follow-up compounds. Novartis said there are no RSV-specific antivirals available at this time, adding that A-60444 is the most advanced small molecule therapy being developed for this indication. The drug is being tested in Phase I/II trials. Company Name Change Company Name Change Genta Inc. Genta Inc. submitted the initial section of a New Drug Application to the Food and Drug Administration for its injectable cancer therapy, Genasense (oblimersen sodium). The NDA seeks accelerated approval for the compound's use in combination with fludarabine plus cyclophosphamide to treat patients with chronic lymphocytic leukemia (CLL) who have previously received fludarabine. Genasense was granted a fast track designation for this indication. Company Name Change Company Name Change OSI Pharmaceuticals Inc. OSI Pharmaceuticals Inc.'s diabetes and obesity unit, Prosidion, granted Merck & Co. Inc. a worldwide, nonexclusive license for a combination therapy comprising a dipeptidyl peptidase IV inhibitor and an unspecified agent; the combination therapy is intended to treat type 2 diabetes and related conditions. In return, OSI will receive up-front, milestone and royalty payments. Additional financial terms of the agreement were not disclosed. Company Name Change Company Name Change Neurochem Inc. Neurochem (International) Ltd. said the Food and Drug Administration will review the company's New Drug Application for Fibrillex, a treatment for amyloid A amyloidosis that was granted fast track and orphan drug status in February of 2004. The NDA includes efficacy and safety data from a single Phase II/III trial. Neurochem and Centocor Inc. entered into an exclusive collaboration and distribution agreement for Fibrillex late last year. Company Name Change Company Name Change Avanir Pharmaceuticals Avanir Pharmaceuticals completed the submission of its New Drug Application to the Food and Drug Administration for Neurodex, a treatment for patients with pseudobulbar affect (PBA). Also referred to clinically as pathological laughing and crying, emotional lability and emotional incontinence, PBA is a neurological condition characterized by the disinhibition or loss of control of the motor expression of emotion. Patients with PBA laugh or cry uncontrollably, often out of context with their social environment. If approved, Neurodex would be the first drug indicated to treat PBA. Company Name Change Company Name Change


	- advertising slogan - b2b branding - best company names - brand architecture - brand association - brand awareness - brand building - brand communication - brand communications - brand creation - brand essence - brand evaluation - brand experience - brand extension - brand extensions - brand id - brand identification - brand image - brand management - brand marketing - brand name generator - brand name product - brand name search - brand personality - brand planning - brand position - brand positioning - brand products - brand profile - brand repositioning - brand revitalization - brand strategist - brand valuation - brand value - brand values - brand vision - branded media - branding a product - branding advertising - branding campaign - branding consultancy - branding consultant - branding consulting - branding design - branding expert - branding experts - branding firm - branding firms - branding guidelines - branding ideas - branding identity - branding logos - branding process - branding products - branding research - branding strategies - branding strategy - branding tools - brandname - brandnames - business branding - business naming - business slogan - catchy slogan - change company name - changing company name - co branding - cobranding - companies name - companies names - company logo - company logos - company name change - company name creator - company name finder - company name generator - company name ideas - company name registration - company name suggestions - company taglines - company titles - conjoint analysis - consumer market research - consumer panels - consumer research - consumer survey - cool company names - corporate identity - corporate identity design - corporate internet branding - corporate logo - corporate name change - corporate name generator - corporation name - corporation names - create a company name - create company name - creating a company name - creative company names - design branding - design company names - digital branding - drug safety - fda approval - fda regulations - find company name - food package design - global branding - global market research - global panel - global survey - good company name - good company names - great company names - healthcare market research - how to choose a company name - how to name a product - how to name your company - ideas for company names - identity branding - image branding - internal branding - international market research - internet branding - internet market research - internet panel - internet poll - internet surveys - law firm names - line extension - logo branding - logo companies - logo company - logo creation - logo design - logo designer - logo designers - logo research - market research panels - market research tools - marketing branding - marketing slogan - name a company - name company - name creation - name development - name generation - name research - names for companies - naming a business - naming a company - naming a product - naming business - naming consultants - naming products - naming service - naming services - naming software - naming standards - naming strategy - naming tools - naming your business - naming your company - new company name - new company names - online market research - package designs - pharmaceutical consultants - physician survey - product brand - product launches - qualitative research - real branding - rebrand - rebranding - register a company name - register company name - registered company names - registering company name - registering company names - research panel - research panels - slogan - slogans - strategic branding - strategic name development - survey panel - survey tool - survey tools - tagline - tagline generator - trade name search - trademark - trademark search - trademark searches - trademark searching - trademarks - unique company names - visual branding - your company name


			Austin / Chicago / Geneva / London / Los Angeles / Miami / New York / Ottawa / Raleigh Durham / Rockville / San francisco / Tokyo